"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
| Descriptor ID |
D015282
|
| MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
| Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
-
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 Sep 01; 58(3):348-356.
-
Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
-
Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device. Circ J. 2018 11 24; 82(12):2931-2938.
-
Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. J Card Fail. 2018 Apr; 24(4):249-254.
-
Multicenter Evaluation of Octreotide as Secondary Prophylaxis in Patients With Left Ventricular Assist Devices and Gastrointestinal Bleeding. Circ Heart Fail. 2017 Nov; 10(11).
-
Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. Cancer Treat Res. 2015; 164:165-94.
-
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.
-
Clinical problem-solving. Needle in a haystack. N Engl J Med. 2009 Feb 05; 360(6):616-21.
-
Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist. Br J Anaesth. 2008 Nov; 101(5):618-26.